At LSC we specialise only in Life Sciences and always keep up to date with leading news, projects and all that’s going on in the industry. As the sector sees continued rapid growth it’s easy to miss some of the major announcements. To make things easier and to ensure you too are well informed we’ve selected and summarised this month’s top Irish Life Science industry news stories below.
MSD seeks permission for major expansion of Carlow plant
MSD has applied for planning permission for a major expansion of its Carlow manufacturing plant. This follow the company’s announcement last October to add 170 jobs to its existing 400-plus workforce in Carlow as it grows its capacity for biologics and vaccines at the site.
The new facilities are expected to begin operations in 2022. This new facility, will be built on a green-field site adjacent to the company’s existing plant in the town. Full article >>
GW Plastics announces 200 jobs for Sligo
GW Plastics has announced plans to expand its advanced manufacturing operations in Sligo, creating over 200 new jobs in the areas of production, quality, regulatory, and engineering.
GW Plastics provides full-service contract manufacturing capabilities with a focus on surgical components, diagnostic devices, and drug delivery systems. The company plans to expand its moulding operations into a scalable 23,000 square foot site in IDA’s Business and Technology Park in Finisklin, Sligo. Full article >>
Meissner to establish manufacturing facility in Castlebar creating 150 jobs
Meissner Filtration Products recently announced that it will expand its manufacturing operations by establishing a facility in County Mayo. Creating upwards of 150 jobs over the next 5 years.
A great vote of confidence for the region as the site was chosen (as part of its first expansion outside of the US ) following a detailed analysis of a number of prospective locations around Europe. Initial operations at the facility will include SUS manufacturing, quality, regulatory and engineering. Full article >>
What are Brexit contingency plans for the UK pharmaceutical industry?
Mike Thompson, the Association of the British Pharmaceutical Industry’s chief executive, described Brexit as the biggest logistical challenge ever faced by the industry.
Potentially driving up manufacturing costs and deterring future investment. Industry executives have warned that investments will halt in the face of mounting uncertainty and worry about their post-Brexit ability to bring highly skilled staff to the UK. Companies have therefore ramped up their preparations for a no-deal Brexit, stockpiling medicines, and duplicating drug testing, transferring licences and making plans to ship drugs to and from the EU. Full article >>